Pricing the EpiPen: Drug Prices, Corporate Governance, and the Financialization of Biomedicine

Why does Mylan’s EpiPen cost so much?

That was a question many parents of food allergic children found themselves asking this past August, as a flurry of news reports revealed that the standard two-pack now costs patients as much as $600 out of pocket. The device, a type of epinephrine auto-injector, looks like an oversized marker. Inside is a mechanism that pops out a short needle and delivers epinephrine in three seconds or less when it is pushed firmly against one’s body (preferably the outer, upper thigh). Epinephrine – a hormone also known as adrenaline – is the preferred substance for halting and reversing a severe allergic reaction, called anaphylaxis. Originally created as a tool for delivering emergency nerve gas treatment on Cold War-era battlefields, the device is now considered a necessity for people with food allergies.

The EpiPen pricing controversy is one of many events that have drawn attention to the escalating price of medical objects and procedures in the past year. Turing Pharmaceuticals’ Daraprim pricing scandal beginning in the fall of 2015 (about which I’ve written previously for Somatosphere) and Theranos’ meltdown earlier in 2016 on the news that the high-priced tests they performed were not as advertised has kept the issue of high drug prices in the public eye. In the EpiPen pricing case, many journalists and members of the food allergy community have critiqued the credentials and motives of Mylan CEO Heather Bresch. From analyses of her possibly fraudulent MBA to critiques of her compensation to her political connections via her US Senator father, her rise to corporate stardom on the strength of EpiPen revenue has been put under the microscope.

One thing that sets these scandals about the costs of medical care apart from previous debates (such as those surrounding the cost of health insurance in the wake of the Affordable Care Act) has been the attention paid to specific pharmaceutical companies and their specific pricing strategies. In each instance, the CEO of the company has been placed in the spotlight, portrayed as both the representative for the complex goings-on within their companies which generate such pricing strategies and an avatar for corporate greed in healthcare. Yet while blaming the CEO satisfies the forensic itch of reporters and congresspeople, it obscures some important structural issues at play in healthcare today. In particular, the methods now used to raise operating capital and bring new products to market have made healthcare CEOs increasingly beholden to a new set of actors with new expectations for company conduct and performance: shareholders, debt-holders, and various types of private investors.

An increasingly important part of research and development for most pharmaceutical companies in the past several years has been to outsource much of the clinical development and manufacturing research to smaller pharmaceutical, biotechnology, medical device, and health technology companies. Small companies conduct the early stages of research and development before their successful “assets” (as new products are called) are scooped up by larger ones via partnerships or acquisitions. These transactions reduce a pharmaceutical company’s infrastructural investment at earlier stages where technologies are more prone to failure due to rocky transitions to use in humans or persistent difficulties in producing the actual drug substance or device. By relying on investors and financiers in new ways to acquire so-called “de-risked” technologies, companies seek to reduce their exposure to the risks of conducting research on and designing products for unruly human bodies.

To attempt such transactions, companies need access to capital, and there are two ways for them to get it: sell more products, or sell them at a high enough price to generate revenue quickly and have cash on hand; or (as Karen Ho (2009) has also explained in her ethnography of investment banking) raise the stock price, which raises the financial valuation of the company (also known as the market capitalization, or market cap), which the company can then borrow against through investment banks and shadowy private equity firms. Mylan’s August 2016 quarterly financial statement bears witness to this strategy, showing that the company raised over $6 billion in capital through debt and stock issuance – essentially borrowing from investors against the promise of future stock price growth – between August 2015 and August 2016. This was almost the precise amount needed for the $6.6 billion takeover of Swedish pharmaceutical company MEDA and associated transaction costs.

EpiPen pricing policies were undoubtedly a crucial lever that enabled this particular transaction. The value provided to a company like Mylan by a device like the EpiPen is not only the value of the revenue collected to date, but also the demonstration of the company’s ability to continue to increase revenue through price increases and increased sales into the future. The promise of increasing revenue draws in new investors as the strategy is demonstrated to work in successive quarters, increasing the company’s stock price and thereby increasing the company’s access to borrowed capital. For modern pharmaceutical companies, this promissory function of pricing is an important aspect of company strategy that enables the pursuit of other activities and transactions.

This episode concerning EpiPen prices – a snapshot in my larger, three-year project on food allergies in the United States – underscores the importance for anthropologists and STS scholars to do more rigorous research on the relationship between medicine and finance. (Notable, Somatosphere has already begun to feature such work in progress.) A number of scholars in what is often referred to as the social studies of finance have now studied how Wall Street-style investment banking gets done in practice (Mackenzie 2006, Riles 2011) and the distinctive cultural attitudes towards risk and reward these practices produce (Ho 2009). Meanwhile, medical anthropologists have written extensively about the construction of consumer and provider markets for pharmaceuticals (Dumit 2012, Greene 2014) as well as how clinical research is strategically designed to provide evidence for lucrative indications for prescribing (Petryna 2009, Jain 2013) and providing hands-on care (Kaufman 2015). What is missing in these literatures as they stand today is an in-depth understanding of the financial practices of healthcare companies and the effects they have on patient care.

These practices matter because they undermine what most assume to be the social role of pharmaceutical companies to be: the development of reasonably priced, high-quality medications for very ill patients. They do so by reinforcing the alignment of management with investors who are interested in making products with large markets that can quickly generate revenues that increase quarter after quarter, thereby generating revenue, increasing share price that can be leveraged as debt in exchange for more capital, or both. In the wake of the shareholder revolution and the widening acceptance of Wall Street financial governance models in healthcare-related businesses, the CEO’s role in pharma has been redefined as one of keeping investors satisfied by assuring them that they will receive their anticipated returns. CEOs who fail at this can be removed by their company boards, as it is not uncommon for the majority of a pharmaceutical company’s board seats – especially those of smaller or new companies – to be populated by representatives of their largest shareholders. The company must be aligned with investor expectations from the top down for the work of making medicines to even begin.

I argue that it is a dead end to try to understand pharmaceutical company behavior – from pricing schemes to early-stage R&D strategies – based on the assumption that drug makers are primarily motivated by a desire to expand access to necessary care. This assumption, which I call the “care thesis of biomedicine,” makes pricing controversies seem contradictory, immoral, even irrational to observers (also see Dingwall 2016 for the impact this has within the medical profession). Understanding the financial entanglements of the modern pharmaceutical company with the financial sector, however, casts a different light on these controversies: they are perfectly rational when measured by the standards of the actors who control the purse strings. In other words, like any actors in ethnographic research, pharmaceutical companies make more sense when apprehended on their own terms. And it is those very terms – what I refer to as the logic of finance capital – that set companies down the path of what many analysts, reporters, and members of the public see as bad behavior that inflicts harm on patients.


Danya Glabau recently received her PhD in Science and Technology Studies (STS) at Cornell University. Her dissertation examined the culture of food allergy activism in the United States and drew on over two years of multisited ethnographic research. She is currently Faculty at The Brooklyn Institute for Social Research and has worked with three New York-based biotechnology companies in the allergy space. You can check out her blog to learn more about her research, upcoming class at the Brooklyn Institute, and other events. You can also follow her on Twitter at @allergyPhD.


Works Cited

Dingwall, Robert. 2016. “Why Are Doctors Dissatisfied? The Role of Origin Myths” 21 (1): 67–70. doi:10.1177/1355819615589425.

Dumit, Joseph. 2012. Drugs for Life: How Pharmaceutical Companies Define Our Health. Durham: Duke University Press.

Greene, Jeremy. 2014. Generic: The Unbranding of Modern Medicine. Baltimore: Johns Hopkins University Press.

Ho, Karen. 2009. Liquidated: An Ethnography of Wall Street. Durham and London: Duke University Press.

Jain, Sarah Lochlann. 2013. Malignant: How Cancer Becomes Us. Berkeley: University of California Press.

Kaufman, Sharon. 2015. Ordinary Medicine: Extraordinary Treatments, Longer Lives, and Where to Draw the Line. Durham, NC: Duke University Press.

Mackenzie, Donald. 2006. An Engine, Not a Camera: How Financial Models Shape Markets. Cambridge, MA: MIT Press.

Petryna, Adriana. 2009. When Experiments Travel: Clinical Trials and the Global Search for Human Subjects. Princeton: Princeton University Press.

Riles, Annelise. 2011. Collateral Knowledge: Legal Reasoning in the Global Financial Markets. Chicago: The University of Chicago Press.



3 replies on “Pricing the EpiPen: Drug Prices, Corporate Governance, and the Financialization of Biomedicine”

Of course. But you still haven’t gotten to what’s important.

Pharmaceutical companies behave like … companies! What a shock!

But in this case, we are talking about a product in a market that is significantly price inelastic. It is a life safer. You keep it around for when you need it, so you don’t be a whole lot of it at once.

And YOU have a monopoly. Unchecked and unregulated when it comes to pricing drugs, you can “charge what the market will bear” – quite a bit. It can be predicted that you will charge substantially more than you would for this drug in a perfectly competitive market, you will end up offering fewer than a competitive market would offer, and you will rake in the dough.

Now, the United States has laws against that, but they’re not enforced any more (I bet most voters never heard of the phrase “trust-busting).”

Why does this make us particularly queasy? Because there are going to be children who die because these creeps are “behaving like a company” instead of behaving like human beings.

Why does this make some of us angry with FDA? Because if a firm is going to allow children to die so they can make monopoly rents, SOMEBODY has to step in, and you’re the most obvious somebody (though actually the Department of Justice should be stepping in – because technically, monopolies are illegal in the United States).

So yeah, of course, the company is behaving like it is. But those are human beings running it, and they don’t have to make this choice.

More to the point – it is prima facia evidence that our private health care markets do not work any more.

A hundred years ago, the US had “most favored nation” status in terms of trade privileges in nations such as China where European states already had gained a foothold. That treaty status meant that the US got the deal that was the best of all those negotiated by the European states.

Somebody explain to me why WE do not have most favored nation status in our OWN country when it comes to pharmaceuticals?

I’m not following what your insight is here. Who, aside from the PR departments of drug companies themselves, profess the “care thesis of biomedicine” and attempt to understand or explain the behavior of these companies as anything other than rationally self-interested? Really, aren’t public corporations generally the example par excellence of entities that we expect to behave in a rationally self-interested manner, often to the detriment of society?

(what needs more light thrown on it is how these corporate self-interests are protected by government agencies who insure that they face little competition)

If your point is that there is dissonance between how markets actually structure biomedicine and how from a normative perspective we think that biomedicine should function, well, that’s been the bailiwick of ethicists like Carl Elliot for several decades, not to mention the exact reason why healthcare markets are so highly regulated (especially outside of the USA).

The research is not uninteresting, but I’m not sure we need ethnography to confirm what healthcare economists have been telling us for some time and what we know in general to be true of public corporations. This is not some heretofore neglected or otherwise opaque area of human activity.

I’m also not sure what the value-free stance of the ethnographer brings to the table but am curiou to read a more general overview of your research goals.

Love your research and willing to bring mine to you to help with it.. I lost my son to food allergies, he had since 12 mo old, the the justice system failed us both during divorce, me seperated by custody battle his life support at the age of 7 his father did not act fast enough to get epi on Halloween 2014. Joseph now an angel. His father lax on how much, I can tell you and I shared. My search has been for years to help the next and help the system for the next.. When this whole Mylan hit the news, it was odd that it was not there months before since we know we have seen the prices and complaints by many way before the highlight.. well took to my blog posted alot that I had researched here are some links, the ” last has links to the other research links.. I will not stop and I thank you for your efforts. I am here to help in anyway. I worked on wallstreet since 1990 so I know the financial side as well.. they received favors vs. stockholder voting rights on mergers.. beyond against law.. too.. alot of favors and contracts to set this one company as well Bayer and Monsanto another research I am doing.. blessings to you and I hope what I placed in my research helps to bring more to yours..

Julianne “A mother of an Angel- Joseph”

Comments are closed.